Grundläggande statistik
| CIK | 1850051 |
SEC Filings
SEC Filings (Chronological Order)
| February 14, 2024 |
SC 13G 1 tm246034d24sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Intelligent Medicine Acquisition Corp (Name of Issuer) Class A (Title of Class of Securities) 45828D205 (CUSIP Number) 12/31/2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to des |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41024 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant a |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of incorporatio |
|
| April 26, 2023 |
Intelligent Medicine Acquisition Corp. Announces it Will Redeem its Public Shares Exhibit 99.1 Intelligent Medicine Acquisition Corp. Announces it Will Redeem its Public Shares BETHESDA, Md, April 26, 2023– Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) (the “Company”), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that because the Company does not believe it will be able to consummate an initial business |
|
| April 17, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-41024 |
|
| April 17, 2023 |
Description of Registrant’s Securities. Exhibit 4.5 DESCRIPTION OF SECURITIES The following descriptions of securities of Intelligent Medicine Acquisition Corporation (the “company,” “Intelligent Medicine,” “we” or “us”) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the company’s amended and restated certificate of incorporation, bylaws and the company’s warrant agreemen |
|
| April 13, 2023 |
SC 13G/A 1 formsc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Intelligent Medicine Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45828D106 (CUSIP Number) February 24, 2023 (Date of Event which Requires Filing of this Statem |
|
| April 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of incorporation |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of incorporatio |
|
| April 3, 2023 |
SEC File Number: 001-41024 CUSIP Number: 45828D106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of incorpora |
|
| February 23, 2023 |
Promissory Note, dated as of February 21, 2023. Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER |
|
| February 23, 2023 |
Promissory Note, dated as of February 21, 2023. Exhibit 10.1 THIS CONVERTIBLE PROMISSORY NOTE (THIS “NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFER |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of incorpora |
|
| February 21, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* INTELLIGENT MEDICINE ACQUISITION CORP. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828D106 (CUSIP Number) Intelligent Medicine Sponsor LLC 9001 Burdette Road Bethesda, MD 20817 (202) 905-5834 (Name, Address and Te |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of in |
|
| February 9, 2023 |
Amendment to Amended and Restated Certificate of Incorporation EX-3.1 2 tm236108d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIGENT MEDICINE ACQUISITION CORP. Pursuant to Section 242 of the Delaware General Corporation Law INTELLIGENT MEDICINE ACQUISITION CORP. (the “Corporation”), a corporation organized and existing under the laws of the State of Delaware, does hereby certify as follows: 1. T |
|
| February 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of in |
|
| February 3, 2023 |
Press Release dated February 3, 2023 Exhibit 99.1 INTELLIGENT MEDICINE ACQUISITION CORP. ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS Bethesda, MD, February 3, 2023 – Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the “Company”) announced today that it has postponed the Company’s Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern T |
|
| February 3, 2023 |
INTELLIGENT MEDICINE ACQUISITION CORP. ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS Exhibit 99.1 INTELLIGENT MEDICINE ACQUISITION CORP. ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS Bethesda, MD, February 3, 2023 – Intelligent Medicine Acquisition Corp. (Nasdaq: IQMD) (the “Company”) announced today that it has postponed the Company’s Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern T |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2023 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of in |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Required in Proxy Statement Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| January 18, 2023 |
United States securities and exchange commission logo January 18, 2023 Gregory Simon Chief Executive Officer Intelligent Medicine Acquisition Corp. |
|
| January 17, 2023 |
United States securities and exchange commission logo January 17, 2023 Gregory Simon Chief Executive Officer Intelligent Medicine Acquisition Corp. |
|
| January 17, 2023 |
CORRESP 1 filename1.htm January 17, 2023 Via edgar U.S. Securities and Exchange Commission Division of Corporation Finance Office of Real Estate & Construction 100 F Street, N.E. Washington, DC 20549 Attention: Kibum Park Jeffrey Gabor Re: Intelligent Medicine Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed January 4, 2023 File No. 001-41024 Ladies and Gentlemen: On behalf of o |
|
| January 4, 2023 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? ? Definitive P |
|
| November 14, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to INTELLIGENT MEDICINE |
|
| August 15, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 17, 2022 |
NT 10-Q 1 tm2215387d2nt10q.htm NT 10-Q SEC File Number: 001-41024 CUSIP Number: 45828D106 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: March 31, 2022 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F |
|
| May 17, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Intelligent Medicine Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45828D205 (CUSIP Number) May 5, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| March 30, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 30, 2022 |
Description of Registrant’s Securities. Exhibit 4.5 DESCRIPTION OF SECURITIES ? The following descriptions of securities of Intelligent Medicine Acquisition Corporation (the ?company,? ?Intelligent Medicine,? ?we? or ?us?) is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to the company?s amended and restated certificate of incorporation, bylaws and the company?s warrant agreem |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Intelligent Medicine Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45828D106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 14, 2022 |
SC 13G/A 1 d314765dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INTELLIGENT MEDICINE ACQUISITION CORP. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828D106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filin |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intelligent Medicine Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828D106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| February 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Intelligent Medicine Acquisition Corp (Name of Issuer) Class A (Title of Class of Securities) 45828D205 (CUSIP Number) 12/31/2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| January 27, 2022 |
HIGHBRIDGE CAPITAL MANAGEMENT LLC - INTELLIGENT MEDICINE ACQUISITION CORP. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Intelligent Medicine Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828D106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to d |
|
| December 23, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of i |
|
| December 23, 2021 |
EX-99.1 2 tm2136187d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Intelligent Medicine Acquisition Corp. Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing December 27, 2021 BETHESDA, Md. – December 23, 2021 – Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) (the “Company” or “Intelligent Medicine”) today announced that the holders of the Company’s units sold in i |
|
| December 20, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to INTELLIGENT MEDICINE |
|
| November 19, 2021 |
HIGHBRIDGE CAPITAL MANAGEMENT LLC - INTELLIGENT MEDICINE ACQUISITION CORP. SC 13G 1 p21-2582sc13g.htm INTELLIGENT MEDICINE ACQUISITION CORP. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intelligent Medicine Acquisition Corp. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828D205** (CUSIP Number) November 9, 2021 (Date of event which r |
|
| November 16, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 tm2132403d28k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4 2021 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or |
|
| November 16, 2021 |
Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Audited Financial Statement of Intelligent Medicine Acquisition Corp.: Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet as of November 9, 2021 F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and Board of Directors of Intelligent Medicine Acquisition Corp. Op |
|
| November 15, 2021 |
Saba Capital Management, L.P. - FORM SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intelligent Medicine Acquisition Corp (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 45828D205 (CUSIP Number) November 5, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| November 12, 2021 |
SC 13G 1 d253249dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INTELLIGENT MEDICINE ACQUISITION CORP. (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) 45828D205 (CUSIP Number) November 5, 2021 (Date of Event Which Requires Filing of th |
|
| November 10, 2021 |
Exhibit 99.2 Intelligent Medicine Acquisition Corp. Announces Closing of Upsized $207,000,000 Initial Public Offering BETHESDA, Md. – November 9, 2021 – Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) (the “Company” or “Intelligent Medicine”) today announced that it closed its upsized initial public offering of 20,700,000 units at a price of $10.00 per unit, including 2,700,000 units purcha |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 INTELLIGENT MEDICINE ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delaware 001-41024 86-2283527 (State or other jurisdiction of in |
|
| November 10, 2021 |
EX-10.6 10 tm2132403d1ex10-6.htm EXHIBIT 10.6 Exhibit 10.6 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into as of this [•] day of [•], 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and [] (“Indemnitee”). WHEREAS, in light of the litigation costs and risks to directors and officers resulting from t |
|
| November 10, 2021 |
Exhibit 1.1 UNDERWRITING AGREEMENT between INTELLIGENT MEDICINE ACQUISITION CORP. and CANTOR FITZGERALD & CO. Dated: November 4, 2021 INTELLIGENT MEDICINE ACQUISITION CORP. UNDERWRITING AGREEMENT New York, New York November 4, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, |
|
| November 10, 2021 |
EX-3.1 3 tm2132403d1ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIGENT MEDICINE Acquisition Corp. November 4, 2021 Intelligent Medicine Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “Intelligent Medicine Acquisition |
|
| November 10, 2021 |
EX-10.3 7 tm2132403d1ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of November 4, 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “Trustee”). |
|
| November 10, 2021 |
EX-10.4 8 tm2132403d1ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of November 4, 2021, is made and entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), Intelligent Medicine Sponsor LLC, a Delaware limited liability company (the “ |
|
| November 10, 2021 |
EX-10.2 6 tm2132403d1ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 WARRANT PURCHASE AGREEMENT THIS WARRANT PURCHASE AGREEMENT (as it may from time to time be amended, this “Agreement”), dated as of November 4, 2021, is entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Cantor Fitzgerald & Co. (the “Purchaser”). WHEREAS, the Company intends to consu |
|
| November 10, 2021 |
EX-10.5 9 tm2132403d1ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 November 4, 2021 Intelligent Medicine Acquisition Corp. 9001 Burdette Rd. Bethesda, MD 20817 Re: Initial Public Offering Ladies and Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and among Intelligent Medicine Acqui |
|
| November 10, 2021 |
Exhibit 10.1 WARRANT PURCHASE AGREEMENT THIS WARRANT PURCHASE AGREEMENT (as it may from time to time be amended, this ?Agreement?), dated as of November 4, 2021, is entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the ?Company?), and Intelligent Medicine Sponsor LLC, a Delaware Limited Liability Company (the ?Purchaser?). WHEREAS, the Company intends to con |
|
| November 10, 2021 |
EX-4.1 4 tm2132403d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of November 4, 2021, is by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”, also referred to herein as t |
|
| November 10, 2021 |
Intelligent Medicine Acquisition Corp. Announces Pricing of $150,000,000 Initial Public Offering EX-99.1 11 tm2132403d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Intelligent Medicine Acquisition Corp. Announces Pricing of $150,000,000 Initial Public Offering BETHESDA, Md. – November 4, 2021 – Intelligent Medicine Acquisition Corp. (NASDAQ: IQMDU) (the “Company” or “Intelligent Medicine”) today announced the pricing of its initial public offering of 15,000,000 units at a price of $10.00 per unit. Th |
|
| November 8, 2021 |
$180,000,000 Intelligent Medicine Acquisition Corp. 18,000,000 Units 424B4 1 tm219664-10424b4.htm 424B4 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(4) Registration No. 333-260205 PROSPECTUS $180,000,000 Intelligent Medicine Acquisition Corp. 18,000,000 Units Intelligent Medicine Acquisition Corp. is a newly organized blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or s |
|
| November 4, 2021 | ||
| November 4, 2021 |
As filed with the United States Securities and Exchange Commission on November 4, 2021. As filed with the United States Securities and Exchange Commission on November 4, 2021. |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Intelligent Medicine Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 86-2283527 (I.R.S. Employer Ide |
|
| November 3, 2021 |
November 3, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Matt Crispino and Jan Woo Re: Intelligent Medicine Acquisition Corp. Registration Statement on Form S-1 Filed October 13, 2021, as amended File No. 333- 260205 Dear Mr. Crispino and Ms. Woo: Pursuant to Rule 461 of the General Rules and Regulations under |
|
| November 3, 2021 |
Intelligent Medicine Acquisition Corp. 9001 Burdette Rd. Bethesda, MD 20817 November 3, 2021 Intelligent Medicine Acquisition Corp. 9001 Burdette Rd. Bethesda, MD 20817 November 3, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Matt Crispino and Jan Woo Re: Intelligent Medicine Acquisition Corp. Registration Statement on Form S-1 File No. 333-260205 Mr. Crispino and Ms. Woo: Pursuant to Rule 461 under |
|
| October 26, 2021 |
Exhibit 10.6 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of [•], 2021, is made and entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), Intelligent Medicine Sponsor LLC, a Delaware limited liability company (the “Sponsor”), and the undersigned parties listed under |
|
| October 26, 2021 |
As filed with the United States Securities and Exchange Commission on October 26, 2021 under the Securities Act of 1933, as amended. |
|
| October 26, 2021 |
Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT between INTELLIGENT MEDICINE ACQUISITION CORP. and CANTOR FITZGERALD & CO. Dated: [ ], 2021 INTELLIGENT MEDICINE ACQUISITION CORP. UNDERWRITING AGREEMENT New York, New York [?], 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Intelligent M |
|
| October 26, 2021 |
PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT EX-10.5 4 tm219664d9ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT This PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT (this “Agreement”) is made as of the [ ] day of [ ] 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Cantor Fitzgerald & Co. (the “Subscriber”). WHEREAS, the Company desires to sell to the S |
|
| October 13, 2021 |
EX-10.3 10 tm219664d7ex10-3.htm EXHIBIT 10.3 Exhibit 10.3 INTELLIGENT MEDICINE ACQUISITION CORP. 9001 Burdette Rd. Bethesda, MD 20817 March 8, 2021 Intelligent Medicine Sponsor LLC 9001 Burdette Rd. Bethesda, MD 20817 Ladies and Gentlemen: Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), is pleased to accept the offer Intelligent Medicine Sponsor LLC, a Delaware limi |
|
| October 13, 2021 |
Exhibit 10.6 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this “Agreement”), dated as of [•], 2021, is made and entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), Intelligent Medicine Sponsor LLC, a Delaware limited liability company (the “Sponsor”), and the undersigned parties listed under |
|
| October 13, 2021 |
EX-10.2 9 tm219664d7ex10-2.htm EXHIBIT 10.2 Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of [•], 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “Trustee”). WHEREAS |
|
| October 13, 2021 |
Exhibit 4.1 NUMBER U- UNITS CUSIP 45828D 205 SEE REVERSE FOR CERTAIN DEFINITIONS INTELLIGENT MEDICINE ACQUISITION CORP. UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE- HALF OF ONE REDEEMABLE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (?Unit?) consists of one (1) share of Class A |
|
| October 13, 2021 |
S-1 1 tm219664-6s1.htm S-1 TABLE OF CONTENTS As filed with the United States Securities and Exchange Commission on October 12, 2021 under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intelligent Medicine Acquisition Corp. (Exact name of regist |
|
| October 13, 2021 |
Consent of Kavita Patel, Director Nominee Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by Intelligent Medicine Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of |
|
| October 13, 2021 |
Consent of Patience Marime-Ball, Director Nominee Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by Intelligent Medicine Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of |
|
| October 13, 2021 |
Exhibit 3.3 BYLAWS OF INTELLIGENT MEDICINE ACQUISITION CORP. ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of Intelligent Medicine Acquisition Corp. (the ?Corporation?) within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or individual acting as the Corp |
|
| October 13, 2021 |
Form of Warrant Purchase Agreement between the Registrant and Intelligent Medicine Sponsor LLC EX-10.4 11 tm219664d7ex10-4.htm EXHIBIT 10.4 Exhibit 10.4 WARRANT PURCHASE AGREEMENT THIS WARRANT PURCHASE AGREEMENT (as it may from time to time be amended, this “Agreement”), dated as of [•], 2021, is entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Intelligent Medicine Sponsor LLC, a Delaware Limited Liability Company (the “Purchaser” |
|
| October 13, 2021 |
EX-10.1 8 tm219664d7ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 [•], 2021 Intelligent Medicine Acquisition Corp. 9001 Burdette Rd. Bethesda, MD 20817 Re: Initial Public Offering Ladies and Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and among Intelligent Medicine Acquisition C |
|
| October 13, 2021 |
Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant Exhibit 4.4 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of [•], 2021, is by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”). WHEREAS, the Company is eng |
|
| October 13, 2021 |
Consent of Joseph L. Schocken, Director Nominee Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by Intelligent Medicine Acquisition Corp. of the Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of |
|
| October 13, 2021 |
EX-3.1 2 tm219664d7ex3-1.htm EXHIBIT 3.1 Exhibit 3.1 CERTIFICATE OF INCORPORATION OF INTELLIGENT MEDICINE ACQUISITION CORP. The undersigned, for the purposes of forming a corporation under the laws of the State of Delaware, does make, file and record this Certificate of Incorporation, and does hereby certify as follows: FIRST. The name of the corporation is Intelligent Medicine Acquisition Corp. ( |
|
| October 13, 2021 |
Specimen Class A Common Stock Certificate EX-4.2 6 tm219664d7ex4-2.htm EXHIBIT 4.2 Exhibit 4.2 NUMBER SHARES C- CUSIP 45828D 106 SEE REVERSE FOR CERTAIN DEFINITIONS INTELLIGENT MEDICINE ACQUISITION CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CLASS A COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE CLASS A COMMON STOCK OF INTELLIGENT MEDICINE ACQUIS |
|
| October 13, 2021 |
Exhibit 10.7 INDEMNIFICATION AGREEMENT This Indemnification Agreement (“Agreement”) is made and entered into as of this [•] day of [•], 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and [ ] (“Indemnitee”). WHEREAS, in light of the litigation costs and risks to directors and officers resulting from their service to companies, and the desire of |
|
| October 13, 2021 |
Promissory Note issued in favor of Intelligent Medicine Sponsor LLC, dated March 8, 2021 EX-10.8 15 tm219664d7ex10-8.htm EXHIBIT 10.8 Exhibit 10.8 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFA |
|
| October 13, 2021 |
Form of Amended and Restated Certificate of Incorporation EX-3.2 3 tm219664d7ex3-2.htm EXHIBIT 3.2 Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIGENT MEDICINE Acquisition Corp. [•], 2021 Intelligent Medicine Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is “Intelligent Medicine Acquisition Corp.” |
|
| October 13, 2021 |
Form of Warrant Purchase Agreement between the Registrant and Cantor Fitzgerald & Co. EX-10.5 12 tm219664d7ex10-5.htm EXHIBIT 10.5 Exhibit 10.5 WARRANT PURCHASE AGREEMENT THIS WARRANT PURCHASE AGREEMENT (as it may from time to time be amended, this “Agreement”), dated as of [•], 2021, is entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Cantor Fitzgerald & Co. (the “Purchaser”). WHEREAS, the Company intends to consummate a |
|
| June 7, 2021 |
TABLE OF CONTENTS Amendment No. 1 to Confidential Draft Submission This is a confidential draft submission to the United States Securities and Exchange Commission on June 4, 2021 under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Intelligent M |
|
| June 7, 2021 |
INVESTMENT MANAGEMENT TRUST AGREEMENT EX-10.2 7 filename7.htm Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of [•], 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company (the “Trustee”). WHEREAS, the Company’s regi |
|
| June 7, 2021 |
Exhibit 4.4 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this ?Agreement?), dated as of [?], 2021, is by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the ?Company?), and Continental Stock Transfer & Trust Company, a New York limited purpose trust company, as warrant agent (the ?Warrant Agent?, also referred to herein as the ?Transfer Agent?). WHEREAS, the Company is eng |
|
| June 7, 2021 |
Exhibit 10.4 WARRANT PURCHASE AGREEMENT THIS WARRANT PURCHASE AGREEMENT (as it may from time to time be amended, this ?Agreement?), dated as of [?], 2021, is entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the ?Company?), and Intelligent Medicine Sponsor LLC, a Delaware limited liability company (the ?Purchaser?). WHEREAS, the Company intends to consummate |
|
| June 7, 2021 |
EX-4.1 3 filename3.htm Exhibit 4.1 NUMBER U- UNITS CUSIP 45828D 205 SEE REVERSE FOR CERTAIN DEFINITIONS INTELLIGENT MEDICINE ACQUISITION CORP. UNITS CONSISTING OF ONE SHARE OF CLASS A COMMON STOCK AND ONE- THIRD OF ONE REDEEMABLE WARRANT, EACH WHOLE WARRANT ENTITLING THE HOLDER TO PURCHASE ONE SHARE OF CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of Units. Each Unit (“Unit”) consists of o |
|
| June 7, 2021 |
[Signature Page to Letter Agreement] Exhibit 10.1 [?], 2021 Intelligent Medicine Acquisition Corp. 9001 Burdette Rd. Bethesda, MD 20817 Re: Initial Public Offering Ladies and Gentlemen: This letter (this ?Letter Agreement?) is being delivered to you in accordance with the Underwriting Agreement (the ?Underwriting Agreement?) to be entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the ?Company?) |
|
| June 7, 2021 |
Exhibit 4.2 NUMBER SHARES C- CUSIP 45828D 106 SEE REVERSE FOR CERTAIN DEFINITIONS INTELLIGENT MEDICINE ACQUISITION CORP. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE CLASS A COMMON STOCK This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF THE PAR VALUE OF $0.0001 EACH OF THE CLASS A COMMON STOCK OF INTELLIGENT MEDICINE ACQUISITION CORP. (THE ?COMPANY?) transferable |
|
| June 7, 2021 |
REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT Exhibit 10.5 REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT THIS REGISTRATION AND STOCKHOLDER RIGHTS AGREEMENT (this ?Agreement?), dated as of [?], 2021, is made and entered into by and among Intelligent Medicine Acquisition Corp., a Delaware corporation (the ?Company?), Intelligent Medicine Sponsor LLC, a Delaware limited liability company (the ?Sponsor?), and the undersigned parties listed under |
|
| June 7, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTELLIGENT MEDICINE Acquisition Corp. [?], 2021 Intelligent Medicine Acquisition Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), DOES HEREBY CERTIFY AS FOLLOWS: 1. The name of the Corporation is ?Intelligent Medicine Acquisition Corp.? The original certificate of incorporation |
|
| June 7, 2021 |
Exhibit 10.6 INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made and entered into as of this [?] day of [?], 2021, by and between Intelligent Medicine Acquisition Corp., a Delaware corporation (the ?Company?), and [ ] (?Indemnitee?). WHEREAS, in light of the litigation costs and risks to directors and officers resulting from their service to companies, and the desire of |
|
| June 4, 2021 |
DRSLTR 1 filename1.htm June 4, 2021 Via edgar U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Folake Ayoola, Esq. Larry Spirgel, Esq. Joseph Cascarano Robert Littlepage Re: Intelligent Medicine Acquisition Corp. Draft Registration Statement on Form S-1 CIK No. 0001850051 Ladies and Gentlemen: On behalf of Intelligent Medici |
|
| April 14, 2021 |
United States securities and exchange commission logo April 14, 2021 Greg Simon Chief Executive Officer and Chief Financial Officer Intelligent Medicine Acquisition Corp. |
|
| March 19, 2021 |
CERTIFICATE OF INCORPORATION INTELLIGENT MEDICINE ACQUISITION CORP. EX-3.1 2 filename2.htm Exhibit 3.1 CERTIFICATE OF INCORPORATION OF INTELLIGENT MEDICINE ACQUISITION CORP. The undersigned, for the purposes of forming a corporation under the laws of the State of Delaware, does make, file and record this Certificate of Incorporation, and does hereby certify as follows: FIRST. The name of the corporation is Intelligent Medicine Acquisition Corp. (the “Corporation”) |
|
| March 19, 2021 |
TABLE OF CONTENTS This is a confidential draft submission to the United States Securities and Exchange Commission on March 19, 2021 under the Securities Act of 1933, as amended. |
|
| March 19, 2021 |
INTELLIGENT MEDICINE ACQUISITION CORP. 9001 Burdette Rd. Bethesda, MD 20817 EX-10.3 4 filename4.htm Exhibit 10.3 INTELLIGENT MEDICINE ACQUISITION CORP. 9001 Burdette Rd. Bethesda, MD 20817 March 8, 2021 Intelligent Medicine Sponsor LLC 9001 Burdette Rd. Bethesda, MD 20817 Ladies and Gentlemen: Intelligent Medicine Acquisition Corp., a Delaware corporation (the “Company”), is pleased to accept the offer Intelligent Medicine Sponsor LLC, a Delaware limited liability company |
|
| March 19, 2021 |
BYLAWS INTELLIGENT MEDICINE ACQUISITION CORP. ARTICLE I EX-3.3 3 filename3.htm Exhibit 3.3 BYLAWS OF INTELLIGENT MEDICINE ACQUISITION CORP. ARTICLE I OFFICES Section 1.1. Registered Office. The registered office of Intelligent Medicine Acquisition Corp. (the “Corporation”) within the State of Delaware shall be located at either (a) the principal place of business of the Corporation in the State of Delaware or (b) the office of the corporation or indivi |
|
| March 19, 2021 |
EX-10.7 5 filename5.htm Exhibit 10.7 THIS PROMISSORY NOTE (THIS “NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE |